Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
University Medical Center Utrecht & Princess Maxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, München, Germany.
Eur J Cancer. 2024 Nov;211:114308. doi: 10.1016/j.ejca.2024.114308. Epub 2024 Sep 6.
The Cell Division Cycle Associated 2 (CDCA2) gene is responsible for encoding a targeting subunit of cell-cycle associated protein. CDCA2 plays a crucial role in various cellular processes, including chromosome segregation and decondensation, nuclear envelope reassembly, microtubule assembly, and DNA damage response. Additionally, CDCA2 is involved in multiple signaling pathways such as the PI3K/Akt pathway and p53 pathway. Undoubtedly, there exists a strong association between CDCA2 and cancer. Numerous studies have reported that elevated levels of CDCA2 are correlated with poor prognosis and several clinicopathological characteristics like tumor size and TNM stage across different types of cancer. Therefore, CDCA2 holds great potential as both a biomarker for diagnosis and a therapeutic target for interventions such as targeted therapies or immunotherapy. Given its promising prospects in scientific research and clinical applications, it is imperative for researchers to delve into the underlying mechanisms of CDCA2 and explore its utilization.
细胞分裂周期相关蛋白 2(CDCA2)基因负责编码细胞周期相关蛋白的靶向亚基。CDCA2 在多种细胞过程中发挥着关键作用,包括染色体分离和去浓缩、核膜重新组装、微管组装和 DNA 损伤反应。此外,CDCA2 还参与多种信号通路,如 PI3K/Akt 通路和 p53 通路。CDCA2 与癌症之间无疑存在着很强的关联。大量研究表明,CDCA2 水平升高与预后不良以及不同类型癌症的多种临床病理特征(如肿瘤大小和 TNM 分期)相关。因此,CDCA2 作为诊断的生物标志物和靶向治疗或免疫治疗等干预措施的治疗靶点具有很大的潜力。鉴于其在科学研究和临床应用中的广阔前景,研究人员必须深入研究 CDCA2 的潜在机制并探索其利用价值。